Revisão Acesso aberto

Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis

2017; Impact Journals LLC; Volume: 8; Issue: 13 Linguagem: Inglês

10.18632/oncotarget.15247

ISSN

1949-2553

Autores

Yanghua Fan, Miaojing Wu, Yuan Jiang, Minhua Ye, Shi-Gang Lu, Lei Wu, Xingen Zhu,

Tópico(s)

RNA modifications and cancer

Resumo

// Yang-Hua Fan 1, * , Miao-Jing Wu 1, * , Yuan Jiang 1 , Minhua Ye 1 , Shi-Gang Lu 1 , Lei Wu 1 , Xin-Gen Zhu 1 1 Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, People’s Republic of China * These authors have contributed equally to the work Correspondence to: Xin-Gen Zhu, email: zxg2008vip@163.com Lei Wu, email: robertcarose@163.com Keywords: HULC, neoplasm, metastasis, prognosis, meta-analysis Received: September 09, 2016     Accepted: January 17, 2017     Published: February 10, 2017 ABSTRACT Since the long non-coding RNA HULC (Highly Upregulated in Liver Cancer) is dysregulated in many cancers, we performed a meta-analysis to determine its prognostic potential in malignant tumors. We searched electronic databases, including PubMed, Medline, OVID, Cochrane Library and Web of Science from inception until August 14, 2016 and identified seven studies with 730 cancer patients for the meta-analysis. We analyzed the hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the relationship between HULC expression and overall survival (OS). We also using RevMan5.3 software to calculate odds ratio (ORs) to assess the association between HULC expression and pathological parameters, including lymph node metastasis (LNM), distant metastasis (DM) and the tumor stage. Our analysis showed that higher HULC expression was associated with OS (HR= 0.50, 95% CI: 0.35–0.70, P <0.00001), LNM (OR=0.20, 95 % CI 0.06–0.64), DM (OR=0.27, 95% CI: 0.13–0.54) and the tumor stage (OR=0.39, 95 % CI 0.25–0.64). These meta-analysis data demonstrate that higher HULC expression can be a useful prognostic biomarker in human cancers.

Referência(s)